cfb4ba65-0b56-4253-bfb3-023c842eb577-PIN

Speed-up the development, availability and access to anti-tuberculosis medicines for children

Status
open for submission
Published
22 Nov 2023
Submission
Null:Null
Tender summary

The subject of this call for tenders is to conclude a service contract for purchasing services to speed up availability and access in the EU to age-appropriate anti-tuberculosis medicines.

What the buyer needs

  • The subject of this call for tenders is to conclude a service contract for purchasing services to speed up availability and access in the EU to age-appropriate anti-tuberculosis medicines.
  • To achieve this goal, the selected contractor will need to carry out clinical and/or non-clinical services for finalising the development and submitting the market authorization for the concerned products for their…

Procurement signals

  • Procedure: HADEA/2023/OP/0052-PIN
  • Procedure type: Source procedure code PRIOR_INFORMATION_NOTICE
  • Contract type: Services contract (31095498)
  • Submission method: Null:Null
  • Published: 22 Nov 2023

Procurement categories

CPV 33600000 CPV 73000000

CPV labels are not yet mapped locally, so the official category codes are shown as source-backed identifiers.

Programme and geography

Programme period 2014 - 2020Programme period 2021 - 2027

Derived from official EU Funding & Tenders portal source fields. Use this as a shortlisting aid; the official tender record remains authoritative.

Source-backed details

Original identifiers and classification fields from the EU tender source.

Procedure identifier
HADEA/2023/OP/0052-PIN
Business identifier
cfb4ba65-0b56-4253-bfb3-023c842eb577-PIN
Procedure type
Source procedure code PRIOR_INFORMATION_NOTICE
Contract type
Services contract (31095498)
Tender timezone
Europe/Brussels
Fetched
1 Jul 2026, 09:21 UTC
Full official description

The subject of this call for tenders is to conclude a service contract for purchasing services to speed up availability and access in the EU to age-appropriate anti-tuberculosis medicines. To achieve this goal, the selected contractor will need to carry out clinical and/or non-clinical services for finalising the development and submitting the market authorization for the concerned products for their commercialisation in the EU.